Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections
The aminoglycosides and cyclic polypeptides are essential drugs in the treatment of multidrug-resistant tuberculosis, underscoring the need for accurate and reproducible drug susceptibility testing (DST). The epidemiological cutoff value (ECOFF) separating wild-type susceptible strains from non-wild...
Gespeichert in:
| Veröffentlicht in: | Journal of Clinical Microbiology 2010-05, Vol.48 (5), p.1853-1858 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1858 |
|---|---|
| container_issue | 5 |
| container_start_page | 1853 |
| container_title | Journal of Clinical Microbiology |
| container_volume | 48 |
| creator | Juréen, P Ängeby, K Sturegård, E Chryssanthou, E Giske, C.G Werngren, J Nordvall, M Johansson, A Kahlmeter, G Hoffner, S Schön, T |
| description | The aminoglycosides and cyclic polypeptides are essential drugs in the treatment of multidrug-resistant tuberculosis, underscoring the need for accurate and reproducible drug susceptibility testing (DST). The epidemiological cutoff value (ECOFF) separating wild-type susceptible strains from non-wild-type strains is an important but rarely used tool for indicating susceptibility breakpoints against Mycobacterium tuberculosis. In this study, we established wild-type MIC distributions on Middlebrook 7H10 medium for amikacin, kanamycin, streptomycin, capreomycin, and viomycin using 90 consecutive clinical isolates and 21 resistant strains. Overall, the MIC variation between and within runs did not exceed ±1 MIC dilution step, and validation of MIC values in Bactec 960 MGIT demonstrated good agreement. Tentative ECOFFs defining the wild type were established for all investigated drugs, including amikacin and viomycin, which currently lack susceptibility breakpoints for 7H10. Five out of seven amikacin- and kanamycin-resistant isolates were classified as susceptible to capreomycin according to the current critical concentration (10 mg/liter) but were non-wild type according to the ECOFF (4 mg/liter), suggesting that the critical concentration may be too high. All amikacin- and kanamycin-resistant isolates were clearly below the ECOFF for viomycin, and two of them were below the ECOFF for streptomycin, indicating that these two drugs may be considered for treatment of amikacin-resistant strains. Pharmacodynamic indices (peak serum concentration [Cmax]/MIC) were more favorable for amikacin and viomycin compared to kanamycin and capreomycin. In conclusion, our data emphasize the importance of establishing wild-type MIC distributions for improving the quality of drug susceptibility testing against Mycobacterium tuberculosis. |
| doi_str_mv | 10.1128/JCM.00240-10 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_552523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>745978796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c676t-89c3cb79efba3fe999c0180d5938da6a1d650122441298f8de58123c03ed9cf93</originalsourceid><addsrcrecordid>eNqNksuO0zAUhiMEYsrAjjWEBWJDBl8Te4NUdbgUtQKJFthZji-thyQudsKoD8E7416YYRYjWBzZOv7Obx-fP8seQ3AGIWKvPkzmZwAgAgoI7mQjCDgryhJ8u5uNAOC0gBBXJ9mDGC8AgIRQej87QQDhCgI0yn59dY0uFtuNyefTSX7uYh9cPfTOdzG3PuTj1nV-1WyVj06bXHY6n2xV41T-yTepbNPv0uOud7XzvVMxX0aj96WLYGTfmq7Pvc3nSaGWqjfBDW3eD7UJamiSaMynnTVqf-PD7J6VTTSPjutptnz7ZjF5X8w-vptOxrNClVXZF4wrrOqKG1tLbA3nXAHIgKYcMy1LCXVJAUSIEIg4s0wbyiDCCmCjubIcn2bFQTdems1Qi01wrQxb4aUTx9T3tDOCUkQRTvzsVr4ZNinqFLsCXXJE6koLDZkVBHArmKlTHkJtFCbYqjLJvbxV7tx9GQsfVmIYBMS0Qvz_8MYNgpYUVQl_fcAT2xqt0gCCbG5U3Tzp3Fqs_E-BWIkZpUngxVEg-B-Dib1oXVSmaWRn_BBFRSivWMXLf5MYU1QSDK97UMHHGIy9eg8EYudjkXws9j5OmYQ_-buHK_iPcRPw_AjIqGRjg-yUi9ccqigmfPd3zw7c2q3Wly4YIWMrLlQrCBNUQEZ30316YKz0Qq5C0ll-RgDiZCrMSEJ-A46JE7Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733526431</pqid></control><display><type>article</type><title>Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections</title><source>American Society for Microbiology</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SWEPUB Freely available online</source><source>PubMed Central</source><creator>Juréen, P ; Ängeby, K ; Sturegård, E ; Chryssanthou, E ; Giske, C.G ; Werngren, J ; Nordvall, M ; Johansson, A ; Kahlmeter, G ; Hoffner, S ; Schön, T</creator><creatorcontrib>Juréen, P ; Ängeby, K ; Sturegård, E ; Chryssanthou, E ; Giske, C.G ; Werngren, J ; Nordvall, M ; Johansson, A ; Kahlmeter, G ; Hoffner, S ; Schön, T</creatorcontrib><description>The aminoglycosides and cyclic polypeptides are essential drugs in the treatment of multidrug-resistant tuberculosis, underscoring the need for accurate and reproducible drug susceptibility testing (DST). The epidemiological cutoff value (ECOFF) separating wild-type susceptible strains from non-wild-type strains is an important but rarely used tool for indicating susceptibility breakpoints against Mycobacterium tuberculosis. In this study, we established wild-type MIC distributions on Middlebrook 7H10 medium for amikacin, kanamycin, streptomycin, capreomycin, and viomycin using 90 consecutive clinical isolates and 21 resistant strains. Overall, the MIC variation between and within runs did not exceed ±1 MIC dilution step, and validation of MIC values in Bactec 960 MGIT demonstrated good agreement. Tentative ECOFFs defining the wild type were established for all investigated drugs, including amikacin and viomycin, which currently lack susceptibility breakpoints for 7H10. Five out of seven amikacin- and kanamycin-resistant isolates were classified as susceptible to capreomycin according to the current critical concentration (10 mg/liter) but were non-wild type according to the ECOFF (4 mg/liter), suggesting that the critical concentration may be too high. All amikacin- and kanamycin-resistant isolates were clearly below the ECOFF for viomycin, and two of them were below the ECOFF for streptomycin, indicating that these two drugs may be considered for treatment of amikacin-resistant strains. Pharmacodynamic indices (peak serum concentration [Cmax]/MIC) were more favorable for amikacin and viomycin compared to kanamycin and capreomycin. In conclusion, our data emphasize the importance of establishing wild-type MIC distributions for improving the quality of drug susceptibility testing against Mycobacterium tuberculosis.</description><identifier>ISSN: 0095-1137</identifier><identifier>ISSN: 1098-660X</identifier><identifier>EISSN: 1098-660X</identifier><identifier>DOI: 10.1128/JCM.00240-10</identifier><identifier>PMID: 20237102</identifier><identifier>CODEN: JCMIDW</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Aminoglycosides - pharmacology ; Antitubercular Agents - pharmacology ; Bacteriology ; Basic Medicine ; Biological and medical sciences ; Culture Media - chemistry ; Fundamental and applied biological sciences. Psychology ; Humans ; Medical and Health Sciences ; MEDICIN ; Medicin och hälsovetenskap ; MEDICINE ; Medicinska och farmaceutiska grundvetenskaper ; Microbial Sensitivity Tests - standards ; Microbiology ; Microbiology in the medical area ; Mikrobiologi inom det medicinska området ; Miscellaneous ; Mycobacteriology and Aerobic Actinomycetes ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - isolation & purification ; Peptides, Cyclic - pharmacology ; TECHNOLOGY ; TEKNIKVETENSKAP ; Tuberculosis - microbiology</subject><ispartof>Journal of Clinical Microbiology, 2010-05, Vol.48 (5), p.1853-1858</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010, American Society for Microbiology 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c676t-89c3cb79efba3fe999c0180d5938da6a1d650122441298f8de58123c03ed9cf93</citedby><cites>FETCH-LOGICAL-c676t-89c3cb79efba3fe999c0180d5938da6a1d650122441298f8de58123c03ed9cf93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2863855/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2863855/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,550,723,776,780,881,3174,3175,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22753499$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20237102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56527$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-135729$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/1618430$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:120403981$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Juréen, P</creatorcontrib><creatorcontrib>Ängeby, K</creatorcontrib><creatorcontrib>Sturegård, E</creatorcontrib><creatorcontrib>Chryssanthou, E</creatorcontrib><creatorcontrib>Giske, C.G</creatorcontrib><creatorcontrib>Werngren, J</creatorcontrib><creatorcontrib>Nordvall, M</creatorcontrib><creatorcontrib>Johansson, A</creatorcontrib><creatorcontrib>Kahlmeter, G</creatorcontrib><creatorcontrib>Hoffner, S</creatorcontrib><creatorcontrib>Schön, T</creatorcontrib><title>Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections</title><title>Journal of Clinical Microbiology</title><addtitle>J Clin Microbiol</addtitle><description>The aminoglycosides and cyclic polypeptides are essential drugs in the treatment of multidrug-resistant tuberculosis, underscoring the need for accurate and reproducible drug susceptibility testing (DST). The epidemiological cutoff value (ECOFF) separating wild-type susceptible strains from non-wild-type strains is an important but rarely used tool for indicating susceptibility breakpoints against Mycobacterium tuberculosis. In this study, we established wild-type MIC distributions on Middlebrook 7H10 medium for amikacin, kanamycin, streptomycin, capreomycin, and viomycin using 90 consecutive clinical isolates and 21 resistant strains. Overall, the MIC variation between and within runs did not exceed ±1 MIC dilution step, and validation of MIC values in Bactec 960 MGIT demonstrated good agreement. Tentative ECOFFs defining the wild type were established for all investigated drugs, including amikacin and viomycin, which currently lack susceptibility breakpoints for 7H10. Five out of seven amikacin- and kanamycin-resistant isolates were classified as susceptible to capreomycin according to the current critical concentration (10 mg/liter) but were non-wild type according to the ECOFF (4 mg/liter), suggesting that the critical concentration may be too high. All amikacin- and kanamycin-resistant isolates were clearly below the ECOFF for viomycin, and two of them were below the ECOFF for streptomycin, indicating that these two drugs may be considered for treatment of amikacin-resistant strains. Pharmacodynamic indices (peak serum concentration [Cmax]/MIC) were more favorable for amikacin and viomycin compared to kanamycin and capreomycin. In conclusion, our data emphasize the importance of establishing wild-type MIC distributions for improving the quality of drug susceptibility testing against Mycobacterium tuberculosis.</description><subject>Aminoglycosides - pharmacology</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Bacteriology</subject><subject>Basic Medicine</subject><subject>Biological and medical sciences</subject><subject>Culture Media - chemistry</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Medical and Health Sciences</subject><subject>MEDICIN</subject><subject>Medicin och hälsovetenskap</subject><subject>MEDICINE</subject><subject>Medicinska och farmaceutiska grundvetenskaper</subject><subject>Microbial Sensitivity Tests - standards</subject><subject>Microbiology</subject><subject>Microbiology in the medical area</subject><subject>Mikrobiologi inom det medicinska området</subject><subject>Miscellaneous</subject><subject>Mycobacteriology and Aerobic Actinomycetes</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Peptides, Cyclic - pharmacology</subject><subject>TECHNOLOGY</subject><subject>TEKNIKVETENSKAP</subject><subject>Tuberculosis - microbiology</subject><issn>0095-1137</issn><issn>1098-660X</issn><issn>1098-660X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNqNksuO0zAUhiMEYsrAjjWEBWJDBl8Te4NUdbgUtQKJFthZji-thyQudsKoD8E7416YYRYjWBzZOv7Obx-fP8seQ3AGIWKvPkzmZwAgAgoI7mQjCDgryhJ8u5uNAOC0gBBXJ9mDGC8AgIRQej87QQDhCgI0yn59dY0uFtuNyefTSX7uYh9cPfTOdzG3PuTj1nV-1WyVj06bXHY6n2xV41T-yTepbNPv0uOud7XzvVMxX0aj96WLYGTfmq7Pvc3nSaGWqjfBDW3eD7UJamiSaMynnTVqf-PD7J6VTTSPjutptnz7ZjF5X8w-vptOxrNClVXZF4wrrOqKG1tLbA3nXAHIgKYcMy1LCXVJAUSIEIg4s0wbyiDCCmCjubIcn2bFQTdems1Qi01wrQxb4aUTx9T3tDOCUkQRTvzsVr4ZNinqFLsCXXJE6koLDZkVBHArmKlTHkJtFCbYqjLJvbxV7tx9GQsfVmIYBMS0Qvz_8MYNgpYUVQl_fcAT2xqt0gCCbG5U3Tzp3Fqs_E-BWIkZpUngxVEg-B-Dib1oXVSmaWRn_BBFRSivWMXLf5MYU1QSDK97UMHHGIy9eg8EYudjkXws9j5OmYQ_-buHK_iPcRPw_AjIqGRjg-yUi9ccqigmfPd3zw7c2q3Wly4YIWMrLlQrCBNUQEZ30316YKz0Qq5C0ll-RgDiZCrMSEJ-A46JE7Q</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Juréen, P</creator><creator>Ängeby, K</creator><creator>Sturegård, E</creator><creator>Chryssanthou, E</creator><creator>Giske, C.G</creator><creator>Werngren, J</creator><creator>Nordvall, M</creator><creator>Johansson, A</creator><creator>Kahlmeter, G</creator><creator>Hoffner, S</creator><creator>Schön, T</creator><general>American Society for Microbiology</general><general>American Society for Microbiology (ASM)</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DG8</scope><scope>DF2</scope><scope>D95</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20100501</creationdate><title>Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections</title><author>Juréen, P ; Ängeby, K ; Sturegård, E ; Chryssanthou, E ; Giske, C.G ; Werngren, J ; Nordvall, M ; Johansson, A ; Kahlmeter, G ; Hoffner, S ; Schön, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c676t-89c3cb79efba3fe999c0180d5938da6a1d650122441298f8de58123c03ed9cf93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aminoglycosides - pharmacology</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Bacteriology</topic><topic>Basic Medicine</topic><topic>Biological and medical sciences</topic><topic>Culture Media - chemistry</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Medical and Health Sciences</topic><topic>MEDICIN</topic><topic>Medicin och hälsovetenskap</topic><topic>MEDICINE</topic><topic>Medicinska och farmaceutiska grundvetenskaper</topic><topic>Microbial Sensitivity Tests - standards</topic><topic>Microbiology</topic><topic>Microbiology in the medical area</topic><topic>Mikrobiologi inom det medicinska området</topic><topic>Miscellaneous</topic><topic>Mycobacteriology and Aerobic Actinomycetes</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Peptides, Cyclic - pharmacology</topic><topic>TECHNOLOGY</topic><topic>TEKNIKVETENSKAP</topic><topic>Tuberculosis - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Juréen, P</creatorcontrib><creatorcontrib>Ängeby, K</creatorcontrib><creatorcontrib>Sturegård, E</creatorcontrib><creatorcontrib>Chryssanthou, E</creatorcontrib><creatorcontrib>Giske, C.G</creatorcontrib><creatorcontrib>Werngren, J</creatorcontrib><creatorcontrib>Nordvall, M</creatorcontrib><creatorcontrib>Johansson, A</creatorcontrib><creatorcontrib>Kahlmeter, G</creatorcontrib><creatorcontrib>Hoffner, S</creatorcontrib><creatorcontrib>Schön, T</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Linköpings universitet</collection><collection>SWEPUB Uppsala universitet</collection><collection>SWEPUB Lunds universitet</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Journal of Clinical Microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Juréen, P</au><au>Ängeby, K</au><au>Sturegård, E</au><au>Chryssanthou, E</au><au>Giske, C.G</au><au>Werngren, J</au><au>Nordvall, M</au><au>Johansson, A</au><au>Kahlmeter, G</au><au>Hoffner, S</au><au>Schön, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections</atitle><jtitle>Journal of Clinical Microbiology</jtitle><addtitle>J Clin Microbiol</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>48</volume><issue>5</issue><spage>1853</spage><epage>1858</epage><pages>1853-1858</pages><issn>0095-1137</issn><issn>1098-660X</issn><eissn>1098-660X</eissn><coden>JCMIDW</coden><abstract>The aminoglycosides and cyclic polypeptides are essential drugs in the treatment of multidrug-resistant tuberculosis, underscoring the need for accurate and reproducible drug susceptibility testing (DST). The epidemiological cutoff value (ECOFF) separating wild-type susceptible strains from non-wild-type strains is an important but rarely used tool for indicating susceptibility breakpoints against Mycobacterium tuberculosis. In this study, we established wild-type MIC distributions on Middlebrook 7H10 medium for amikacin, kanamycin, streptomycin, capreomycin, and viomycin using 90 consecutive clinical isolates and 21 resistant strains. Overall, the MIC variation between and within runs did not exceed ±1 MIC dilution step, and validation of MIC values in Bactec 960 MGIT demonstrated good agreement. Tentative ECOFFs defining the wild type were established for all investigated drugs, including amikacin and viomycin, which currently lack susceptibility breakpoints for 7H10. Five out of seven amikacin- and kanamycin-resistant isolates were classified as susceptible to capreomycin according to the current critical concentration (10 mg/liter) but were non-wild type according to the ECOFF (4 mg/liter), suggesting that the critical concentration may be too high. All amikacin- and kanamycin-resistant isolates were clearly below the ECOFF for viomycin, and two of them were below the ECOFF for streptomycin, indicating that these two drugs may be considered for treatment of amikacin-resistant strains. Pharmacodynamic indices (peak serum concentration [Cmax]/MIC) were more favorable for amikacin and viomycin compared to kanamycin and capreomycin. In conclusion, our data emphasize the importance of establishing wild-type MIC distributions for improving the quality of drug susceptibility testing against Mycobacterium tuberculosis.</abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>20237102</pmid><doi>10.1128/JCM.00240-10</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0095-1137 |
| ispartof | Journal of Clinical Microbiology, 2010-05, Vol.48 (5), p.1853-1858 |
| issn | 0095-1137 1098-660X 1098-660X |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_552523 |
| source | American Society for Microbiology; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SWEPUB Freely available online; PubMed Central |
| subjects | Aminoglycosides - pharmacology Antitubercular Agents - pharmacology Bacteriology Basic Medicine Biological and medical sciences Culture Media - chemistry Fundamental and applied biological sciences. Psychology Humans Medical and Health Sciences MEDICIN Medicin och hälsovetenskap MEDICINE Medicinska och farmaceutiska grundvetenskaper Microbial Sensitivity Tests - standards Microbiology Microbiology in the medical area Mikrobiologi inom det medicinska området Miscellaneous Mycobacteriology and Aerobic Actinomycetes Mycobacterium tuberculosis Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Peptides, Cyclic - pharmacology TECHNOLOGY TEKNIKVETENSKAP Tuberculosis - microbiology |
| title | Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T23%3A41%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Wild-Type%20MIC%20Distributions%20for%20Aminoglycoside%20and%20Cyclic%20Polypeptide%20Antibiotics%20Used%20for%20Treatment%20of%20Mycobacterium%20tuberculosis%20Infections&rft.jtitle=Journal%20of%20Clinical%20Microbiology&rft.au=Jur%C3%A9en,%20P&rft.date=2010-05-01&rft.volume=48&rft.issue=5&rft.spage=1853&rft.epage=1858&rft.pages=1853-1858&rft.issn=0095-1137&rft.eissn=1098-660X&rft.coden=JCMIDW&rft_id=info:doi/10.1128/JCM.00240-10&rft_dat=%3Cproquest_swepu%3E745978796%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733526431&rft_id=info:pmid/20237102&rfr_iscdi=true |